NEW
YORK, July 28, 2023 /PRNewswire/ -- Jakubowitz
Law announces that a securities fraud class action
lawsuit has commenced on behalf of shareholders of NovoCure Limited
(NASDAQ: NVCR).
To receive updates on the lawsuit, fill out the
form:
https://claimyourloss.com/securities/novocure-class-action-loss-submission-form/?id=42663&from=4
The lawsuit seeks to recover losses for shareholders who
purchased NovoCure between January 5,
2023 and June 5, 2023.
Shareholders interested in acting as a lead plaintiff
representing the class of wronged shareholders have until
August 18, 2023 to petition
the court. Your ability to share in any recovery doesn't require
that you serve as a lead plaintiff.
According to a filed complaint, NovoCure Limited issued
materially false and/or misleading statements and/or failed to
disclose that: (i) the Company concealed the true nature of the
LUNAR study data, including that the study relied on a relatively
small percentage of study participants that had been receiving
standard of care therapy; (ii) as a result, the data was materially
less reliable in terms of demonstrating clinical efficacy; (iii)
the foregoing, once revealed, was reasonably likely to have a
material negative impact on the Company's regulatory prospects and
operations; and (iv) as a result, the Company's public statements
were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities
fraud. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/nvcr-shareholder-alert-jakubowitz-law-reminds-novocure-shareholders-of-a-lead-plaintiff-deadline-of-august-18-2023-301887889.html
SOURCE Jakubowitz Law